Updated:
Dilon Technologies
Dilon Technologies, headquartered in Newport News, United States, was established in 1999. The company develops molecular imaging products and services for...
Dilon Technologies
Dilon Technologies, headquartered in Newport News, United States, was established in 1999. The company develops molecular imaging products and services for early cancer detection. It has secured $9 million in total funding.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Newport News
Corporate office
Newport News, VA, United States
Additional offices
Caesarea, Israel
Sector focus
Frequently asked questions
What medical devices does Dilon Technologies manufacture?
Dilon's portfolio includes the Navigator System (a surgical gamma probe for radio-guided surgery), MarginProbe (for real-time breast cancer margin assessment), the CoPilot VL+ (a portable video laryngoscope), and HEMOBLAST Bellows (a powdered hemostat). The company also produces the TrueView 200 Pro for radiography and Navigator Sterilization probes (per the firm's website).
In how many countries does Dilon Technologies operate?
The firm states on its website that its devices are used in over 76 countries worldwide. It maintains a headquarters in Newport News, Virginia, and an Israeli subsidiary, Dilon Medical Technologies Ltd., in Caesarea.
Is Dilon Technologies structured as a family office or an operating company?
Dilon Technologies presents itself as a medical device manufacturer, not a family office. No public information indicates it manages capital for a family or functions as an investment firm. Its AUM is undisclosed, and it does not claim any investment management activities.
Who owns Dilon Technologies?
Ownership of Dilon Technologies is not publicly disclosed. The company's website does not list founders, shareholders, or investors. No independent sources provide ownership details.
Does Dilon Technologies have a research or clinical data publication record?
The company's website references published data for MarginProbe and mentions an enrollment start for a "Next Generation MarginProbe" trial. Specific publication details or clinical trial registries are not linked on the site.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: